Global Antibody Drug Conjugates Market Size, Trends, and Growth Opportunity, By Product Type (Adcetris, Kadcyla, and Others), By Application (Blood Cancer, Breast Cancer, Urothelial/Bladder Cancer), By Technology (Cleavable, Non-cleavable), By Region and Forecast to 2030.
Global Antibody Drug Conjugates Market
The Global Antibody Drug Conjugates Market was valued at USD 6.75 billion in 2022 and is expected to expand to USD 21.85 billion by 2030, at a CAGR of 12.70% during the forecast period 2023-2030.
Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs that are designed as targeted therapy for the treatment of cancer. Unlike chemotherapy, antibody-drug conjugates are intended to aim and kill tumor cells while sparing healthy cells.
Market Drivers
The global antibody drug conjugates market is mainly driven by rising incidences of cancer worldwide. According to the Cancer Research of the UK, the number of new cancer cases globally is expected to reach approx. 27.9 million by 2040. Main factors such as smoking, obesity, alcohol, and unhealthy diet are the major reasons for increasing cancer cases worldwide.
Furthermore, funding & investment in this field by the key players for the development of new antibody-drug conjugates intended for the treatment of cancer is expected to drive the global antibody-drug conjugates market growth. Also, advanced technological advancements are driving the growth of the market.
Market Restraints
The high cost of treatment & procedures, various stringent government regulations & FDA approvals, and lack of funds are expected to restrain the global antibody drug conjugates market growth over the forecast period of 2030.
Market Segmentation
The global antibody drug conjugates market is segmented into product type, application, technology, and region
Based on product type, the global antibody drug conjugates market is segmented into adcetris, kadcyla, and others.
Further, based on application, the global antibody drug conjugates market is segmented into blood cancer, breast cancer, and urothelial/bladder cancer.
Regional Analysis
The global antibody drug conjugates market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
The North American region is expected to dominate the global antibody drug conjugates market in terms of revenue in 2022. The well-established research infrastructure for the development of novel antibody-drug conjugates, growing per capita healthcare expenditure, and rising prevalence of cancer are the major factors responsible for the growth of the region.
The Asia Pacific region antibody-drug conjugates market is projected to witness significant growth in CAGR during the forecast period. The growth of the region is attributable to the approval of new novel antibody-drug conjugates in the region.
Key Players
Various key players are discussed in the global antibody drug conjugates market report including; Seagen, Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, F. Hoffmann-La Roche Ltd., Pfizer, Inc., Gilead Sciences, Inc., Daiichi Sankyo Company Limited, GlaxoSmithKline plc, Astellas Pharma, Inc., ADC Therapeutics SA, and Others.
For instance, in February 2022, CDMO Piramal Pharma Solutions invested around $74.6 million in the development of 2 new antibody-drug conjugates production facilities at its existing sites in Grange mouth, Scotland to fulfill the rising demand for commercial antibody-drug conjugates in the UK.
Market Taxonomy
By Product Type
• Adcetris
• Kadcyla
• Others
By Application
• Blood Cancer
• Breast Cancer
• Urothelial/Bladder Cancer
By Technology
• Cleavable
• Non-cleavable
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa
Global Antibody Drug Conjugates Market
1 Introduction
1.1 Objective of the Study
1.2 Market Definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Antibody Drug Conjugates Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Cumulative Impact Due To Recent Energy Crisis
4.2.5 Cumulative Impact Due Nearing Economic Downturn
4.2.6 Post Covid-19 World Supply and Demand Conditions
4.2.7 Cumulative Impact Of Russia-Ukraine Conflict
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Antibody Drug Conjugates Market, By Product Type
5.1 Y-o-Y Growth Comparison, By Product Type
5.2 Global Antibody Drug Conjugates Market Share Analysis, By Product Type
5.3 Global Antibody Drug Conjugates Market Size and Forecast, By Product Type
5.3.1 Adcetris
5.3.2 Kadcyla
5.3.3 Others
6 Global Antibody Drug Conjugates Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Antibody Drug Conjugates Market Share Analysis, By Application
6.3 Global Antibody Drug Conjugates Market Size and Forecast, By Application
6.3.1 Blood Cancer
6.3.2 Breast Cancer
6.3.3 Urothelial/Bladder Cancer
7 Global Antibody Drug Conjugates Market, By Technology
7.1 Y-o-Y Growth Comparison, By Technology
7.2 Global Antibody Drug Conjugates Market Share Analysis, By Technology
7.3 Global Antibody Drug Conjugates Market Size and Forecast, By Technology
7.3.1 Cleavable
7.3.2 Non-cleavable
8 Global Antibody Drug Conjugates Market, By Region
8.1 Global Antibody Drug Conjugates Market Share Analysis, By Region
8.2 Global Antibody Drug Conjugates Market Share Analysis, By Region
8.3 Global Antibody Drug Conjugates Market Size and Forecast, By Region
9 North America Antibody Drug Conjugates Market Analysis and Forecast (2023-2030)
9.1 Introduction
9.2 North America Antibody Drug Conjugates Market Share Analysis, By Product Type
9.3 North America Antibody Drug Conjugates Market Share Analysis, By Application
9.4 North America Antibody Drug Conjugates Market Size and Forecast, By Technology
9.5 North America Antibody Drug Conjugates Market Size and Forecast, By Country
9.5.1 U.S.
9.5.2 Canada
9.5.3 Mexico
10 Europe Antibody Drug Conjugates Market Analysis and Forecast (2023-2030)
10.1 Introduction
10.2 Europe Antibody Drug Conjugates Market Share Analysis, By Product Type
10.3 Europe Antibody Drug Conjugates Market Share Analysis, By Application
10.4 Europe Antibody Drug Conjugates Market Size and Forecast, By Technology
10.5 Europe Antibody Drug Conjugates Market Size and Forecast, By Country
10.5.1 Germany
10.5.2 France
10.5.3 UK
10.5.4 Rest of Europe
11 Asia Pacific Antibody Drug Conjugates Market Analysis and Forecast (2023-2030)
11.1 Introduction
11.2 Asia Pacific Antibody Drug Conjugates Market Share Analysis, By Product Type
11.3 Asia Pacific Antibody Drug Conjugates Market Share Analysis, By Application
11.4 Asia Pacific Antibody Drug Conjugates Market Size and Forecast, By Technology
11.5 Asia Pacific Antibody Drug Conjugates Market Size and Forecast, By Country
11.5.1 China
11.5.2 Japan
11.5.3 India
11.5.4 Rest of Asia Pacific
12 Latin America Antibody Drug Conjugates Market Analysis and Forecast (2023-2030)
12.1 Introduction
12.2 Latin America Antibody Drug Conjugates Market Share Analysis, By Product Type
12.3 Latin America Antibody Drug Conjugates Market Share Analysis, By Application
12.4 Latin America Antibody Drug Conjugates Market Size and Forecast, By Technology
12.5 Latin America Antibody Drug Conjugates Market Size and Forecast, Country
12.5.1 Brazil
12.5.2 Rest of Latin America
13 Middle East Antibody Drug Conjugates Market Analysis and Forecast (2023-2030)
13.1 Introduction
13.2 Middle East Antibody Drug Conjugates Market Share Analysis, By Product Type
13.3 Middle East Antibody Drug Conjugates Market Share Analysis, By Application
13.4 Middle East Antibody Drug Conjugates Market Size and Forecast, By Technology
13.5 Middle East Antibody Drug Conjugates Market Size and Forecast, By Country
13.5.1 Saudi Arabia
13.5.2 UAE
13.5.3 Egypt
13.5.4 Kuwait
13.5.5 South Africa
14 Competitive Analysis
14.1 Competition Dashboard
14.2 Market Share Analysis of Top Vendors
14.3 Key Development Strategies
15 Company Profiles
15.1 Seagen, Inc.
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 Takeda Pharmaceutical Company Limited
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.25 Key Market Developments
15.2.6 Key Strategies
15.3 AstraZeneca
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 F. Hoffmann-La Roche Ltd.
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Pfizer, Inc.
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Gilead Sciences, Inc.
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Daiichi Sankyo Company Limited
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 GlaxoSmithKline plc
15. 8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 Astellas Pharma, Inc.
15.9.1 Overview
15.9.2 Offerings
15.4.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies
15.10 ADC Therapeutics SA
15.10.1 Overview
15.10.2 Offerings
15.10.3 Key Financials
15.10.4 Business Segment & Geographic Overview
15.10.5 Key Market Developments
15.10.6 Key Strategies
